起始别嘌醇采用「起始低剂量缓慢加量」方案时低剂量秋水仙碱预防的成本效果:来自非劣效随机双盲安慰剂对照试验的证据
该非劣效随机双盲安慰剂对照试验纳入200例痛风患者,在起始别嘌醇并每月加量至血尿酸<0.36 mmol/L的过程中,比较秋水仙碱0.5 mg每日一次与安慰剂预防痛风发作的成本效果。6个月和1年时秋水仙碱组平均费用均更高,增量净货币效益分别为-$1,373和-$3,191,成本效果概率分别为17.7%和1.5%,结论为12个月内不太可能具有成本效果。
要点
- 秋水仙碱组6个月和1年平均费用均高于安慰剂组,调整后平均差值分别为$1,848和$2,282。
- 6个月和12个月增量净货币效益分别为-$1,373和-$3,191,成本效果概率分别为17.7%和1.5%。
- 作者结论认为起始别嘌醇时6个月低剂量秋水仙碱预防在12个月内不太可能具有成本效果。
核心结论
- 起始别嘌醇采用「起始低剂量缓慢加量」方案时,6个月低剂量秋水仙碱预防在12个月内不太可能具有成本效果。
研究设计与样本
- 非劣效随机双盲安慰剂对照试验,纳入符合美国风湿病学会起始降尿酸治疗推荐且血尿酸≥0.36 mmol/L(6 mg/dL)的痛风患者200例,按1:1随机分配至秋水仙碱0.5 mg每日一次(n=100)或安慰剂(n=100),治疗6个月并再随访6个月。
- 所有参与者均接受别嘌醇,每月增加剂量以达到目标血尿酸<0.36 mmol/L。
主要发现
- 秋水仙碱组6个月和1年平均费用均高于安慰剂组,调整后平均差值分别为$1,848(95%CI -$321至$4,017)和$2,282(95%CI -$173至$4,737)。
- 秋水仙碱组6个月质量调整生命年略高(调整后平均差值0.008,95%CI -0.020至0.035),但1年时较低(-0.015,95%CI -0.039至0.010)。
- 秋水仙碱在6个月和12个月均未发现具有成本效果,增量净货币效益分别为-$1,373(95%CI -$4,287至$1,542)和-$3,191(95%CI -$6,274至-$107),成本效果概率分别为17.7%和1.5%。
- 从社会视角获得相似结果。
关键数值与推荐
- 主要结局为6个月和1年随访时从卫生系统视角的增量成本效果,以支付意愿阈值相当于人均国内生产总值时的增量净货币效益衡量。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to investigate the cost-effectiveness of low-dose colchicine prophylaxis for preventing gout flares when starting allopurinol using the "start-low go-slow" approach. METHODS: Participants with gout, fulfilling the American College of Rheumatology recommendations for starting urate-lowering therapy and with serum urate ≥0.36 mmol/L (6 mg/dL), were randomly allocated (1:1) to either colchicine (0.5 mg daily) or placebo for six months with a further six-month follow-up. All participants received allopurinol, with monthly increase in dose to achieve target urate <0.36 mmol/L. The primary outcomes were incremental cost-effectiveness at the 6-month and 1-year follow-up from the health system perspective, measured by incremental net monetary benefit (INMB) at a willingness-to-pay threshold equivalent to gross domestic product per capita. RESULTS: Two hundred participants were randomized to either colchicine (n = 100) or placebo (n = 100). Mean costs were higher in the colchicine group over both six months and one year (adjusted mean difference $1,848 [95% confidence interval (CI) -$321 to $4,017] and $2,282 [95% CI -$173 to $4,737], respectively). Quality-adjusted life years were slightly higher in the colchicine group over six months (adjusted mean difference 0.008 [95% CI -0.020 to 0.035]) but lower over one year (-0.015 [95% CI -0.039 to 0.010]). Treatment with colchicine was not found to be cost-effective at either 6 months or 12 months (INMB -$1,373 [95% CI -$4,287 to $1,542] and -$3,191 [95% CI -$6,274 to -$107], probability of cost-effectiveness 17.7% and 1.5%, respectively). Similar results were obtained from a societal perspective. CONCLUSION: Six months of low-dose colchicine prophylaxis when starting allopurinol using the "start-low go-slow" approach is unlikely to be cost-effective over 12 months.
引用
- Pryymachenko Y, Wilson R, Dalbeth N, et al. Cost-Effectiveness of Low-Dose Colchicine Prophylaxis When Starting Allopurinol Using the "Start-Low Go-Slow" Approach for Gout: Evidence From a Noninferiority Randomized Double-Blind Placebo-Controlled Trial. Arthritis Care Res (Hoboken). 2025. PMID: 40827007. doi:10.1002/acr.25631
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。